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STUDY OF ANTIRETROVIRAL MUTANTS IN HIV PATIENTS WITH TREATMENT FAILURES
AND THE EFFECT OF RISK FACTORS IN THE VIROLOGICAL FAILURES
Lizeth TAYLOR-CASTILLO(1), Gisela HERRERA-MARTÍNEZ(2), María Paz LEÓN-BRATTI(3), Ricardo BOZA(4), Bernal LEÓN-RODRÍGUEZ(1),
Ronald B. LUFTIG(1) & Kirsten VISONÁ(1)
SUMMARY
Introduction: Information about HIV phenotypes of resistant to available ART and the influence of different risk factors on
virological failures (VF) in Costa Rican HIV positive patients prior or during HAART is unknown.
Materials and methods: Eighty nine samples, 72 VF and 17 basal (before treatment) were analyzed by examining resistant
mutants in reverse transcriptase (RT) and protease (PT) regions using Trugene or LIPA genotyping kits. Sixty eight control
patients were selected and relevant information was collected in a questionnaire.
Results: Poor adherence, presence of resistant mutations and number of treatment’s changes were the only significant factors
found (p = 0.006, 0.04 and 0.01 respectively). From 66 sequenced samples, 78%, 50% and 50% showed resistance to NRTI
(nucleoside reverse transcriptase inhibitors), NNRT (non-nucleoside reverse transcriptase inhibitors) and PI (protease inhibitors),
respectively. The most frequent mutations were M41L, M184V, and T215FY in RT and L62PI, L10FIRV and M36I in PT.
Discussion: The most important factor related to treatment response in this study was adherence to treatment. Mutations in RT
were related to the treatment failure while the ones found in PT were secondary mutations which have been previously described
to influence the selection of primary resistance mutations in these regions. The study reveals the urgency to detect resistant
mutations in VF to be considered by physicians for selection of treatment schedule, to analyze basal HIV patients for monitoring
of the spread of resistant mutations and the importance to reinforce the adherence in the patients for overall treatment outcome.
KEYWORDS: Human immunodeficiency virus; Anti-retroviral treatment; Resistance mutations; Highly active antiretroviral
therapy; Risk factors; Response; Adherence.
INTRODUCTION
An estimated of 40 million people are infected with HIV/AIDS in
the world, 90% in developing countries and of these five to six million
are in need of anti-retroviral treatment (ART)11,19. ART reduces
morbidity and mortality associated with HIV infection and enhances
recovery of impaired immunologic function in most cases. However,
these drugs also increase the possibility of developing resistance in
patients with incomplete viral suppression9,11,16,17,19. Furthermore, ART
is often not available in developing countries due to its high cost, a
situation that was declared a global health emergency by the World
Health Organization (WHO). Thus, in 2001 a partnership was launched
between United Nations organizations and six major pharmaceutical
companies in order to lower the prices of ART in developing countries
which participated in the accelerated access initiative (AAI)19.
There is extensive documentation about development of mutants
resistant to highly active antiretroviral therapy (HAART), as well as
its occurrence in certain individuals before treatment. Important factors
that influence the development of mutations include: poor patient
compliance, high initial viral load, low basal CD4 levels, HIV subtype,
co-infections with other agents, sub optimal drug levels and interaction
with other drugs that would affect absorption, elimination and adverse
reactions 2,5,15,26,30.
In Costa Rica, the Social Security System (SSS) initiated HAART
in 1997 with universal coverage in all the country, and approximately
1800 patients are under treatment at the present time. This situation
represents a high cost for the SSS.
Virological failure (VF) is a reality accompanying ART and requires
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prompt detection and characterization of associated resistant mutants,
in order to change the treatment to the most suitable scheme and stop
accumulation of more mutants that could jeopardize treatment outcome.
The test of drug resistance is highly recommended and even more so
in developing countries where, drug options, monitoring tools, and
alternative therapeutic schemes are limited6,9,13,23.
Sequence-based genotyping assays to determine ART resistant
mutants have been developed by different commercial companies. These
assays are complex, requiring careful technical performance and data
interpretation, consistent test procedures and strict quality control to
ensure reliable results. The understanding of the characteristics,
limitations of the assay and complexity of resistance patterns is required
for a consequent and trusty interpretation of drug test results6,10,14,25.
In Central America there are no published studies defining the
degree of HIV diversity and the existence of phenotypes resistant to
available ART.
The aim of this study was to detect and characterize ART resistant
mutants in Costa Rican HIV positive patients prior or during HAART
and with VF, to analyze the influence of different risk factors on the
appearance of VF, as well as to evaluate the benefits of using resistant
mutant information in order to choose an adequate treatment regimen.
MATERIALS AND METHODS
Study population: A total of 89 patients were selected from the
SSS in Costa Rica during 2003, 72 from patients receiving HAART
with VF and 17 basal samples from patients before treatment. VF was
defined as an increase of viral load of ≥ 1 x 103 copies/mL in two
consecutive samples (Infectology Committee Criteria, SSS). A blood
sample was collected from each patient (VF and basal) and the plasma
was referred to the International Center of Medical Research and
Training (ICMRT) and kept frozen below -40 °C until analyzed.
In addition 68 HIV infected individuals with HAART and without
VF were selected as controls, matched in age and period of treatment.
Data collection: Each patient signed a consent form and a
questionnaire was completed for each patient and control, based on
the clinical record with the following information: HIV viral load
(copies/mL), CD4 count (cells/mm3), sex, age, place of residence, risk
group (men who have sex with men, heterosexual, intravenous drug
users), clinical presentation (AIDS, AIDS associated complex (ARC),
asymptomatic), treatment initiation date, type of treatment,
opportunistic infections, depression (yes or no), education level (no
education, primary, secondary and university education), occupation
(professional, technical businessman, manual worker, housewife),
alcohol consumption (yes or no), use of illicit drugs (type of drug),
adherence (good or bad, good adherence was defined as over 95%
compliance with the prescribed regimen), type and change of treatment.
Methods: A total of 89 samples (72 VF and 17 basal) and the 68
samples of control group, were analyzed by viral load using the kit
Amplicore HIV-1 version 1.5 (Roche, USA) according to
manufacturer’s instructions. Each sample from a patient with VF was
sequenced by the method of Trugene and basal samples analyzed using
LIPA. Both methods permitted the detection of resistant mutants of
the HIV RT and PT.
RNA Extraction, RT-PCR and sequencing: RNA was extracted
from 1 mL of previously centrifuged (23,500 x g for 1 h at 8 °C) plasma
samples, using a silica gel system QIAamp Viral RNA mini kit (Qiagen
Inc, CA.). An RT-PCR of pol. gene of HIV was done and after sequenced
for both the RT and PT region of interest with the Trugene HIV-1
Genotyping Kit (Visible Genetics, Canada) according to manufacture’s
instructions. Sequences analysis was performed using the Gene Open
System and the VG Gene Librarian HIV Module, version 3.1.6 6(Visible
Genetics, Canada).
Analysis of basal samples was done by LIPA, courtesy of
Innogenetics, Inc., at Gent, Belgium23.
Statistical Analysis: Analysis of the different variables was carried
out using SPSS software. The X2 test with an α value of less than 0.05
was defined as significant. A logistic regression was used to identify
the most important variables associated to VF.
RESULTS
Patients with VF were predominantly males (88.4%), 64.5% were
men who have sex with men and 89% were between 21 and 50 years
old. Of these patients 46% had basal viral load of ≥ 105 copies/mL and
56% showed a basal CD4 count < 200-cells/µL.
The level of CD4 in the last samples, was > 200 cells/µL in 94% of
the control group and 70% of VF patients; with mean values of 551
and 343.75 cells/µL, respectively. The mean basal CD4 level in control
and VF patient was 189.8 and 166.8 cells/µL respectively. All controls
had viral loads < 103 copies/mL; in contrast only 7% of the VF patients
(ρ ≤ 0.000) with mean values of < 50 copies/mL and 1.3 x 105 for each
group, respectively (Figs. 1 and 2). The mean basal viral load was 1.8
x 105 for the VF patient and 1.67 x 105 for the control group.
Also, 68.7% of VF patients were clinically diagnosed as AIDS or
ARC compared to only 17.7% in the control group.
Fig. 1 - CD4 level in 68 basal samples of the control group (BC), 55 basal samples of the VF
patient (BP), 67 last sample in the control group (CG), and 67 last sample in the VF patient
(PG), analyzed during 2003.
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Of the risk factors analyzed, the following were found to be associated
with VF: poor adherence, history of depression, occupation (no
professional or technical), low education level, alcohol ingestion, clinical
presence of AIDS and/or ARC, type of initial ART, presence of resistant
mutants and the number of change of treatment (Table 1). This association
persisted only for poor adherence, presence of resistant mutants and the
number of change of treatment after a logistic regression analysis (p =
0.006, 0.04, 0.01 respectively). The OR to adherence was 63.5 (3.1-
1269.1; CI 95%), to change of treatment was 44.1 (2.4-809.5; CI 95%)
and 11.4 (1.0-129.1; CI 95%) to resistant mutants.
The 60% of the patients showed good response to zidovudine,
lamivudine, indinavir but only 29% to zidovudine, lamivudine,
nelfinavir. When analyzing the adherence, a higher level was found
when using indinavir vs. nelfinavir.
Of 72 samples analyzed for ART resistant mutants only 66 could
be amplified. In these samples resistance to at least one family of
antiretroviral drugs was observed: 51 samples (78%), showed resistance
to NRTI, 33 (50%) to NNRT and 33 (50%) to PI. A mixture of resistance
mutants to NRTI and PI was observed in 49% of the samples and 24%
presented at least one resistance to each of the three types of drugs.
The frequency of mutations related to partial or total resistance to
one or more ART is shown in Table 2. The three most frequent mutations
for RT were M41L, M184V, and T215FY. These mutations were
previously described to cause resistance to zidovudine, lamivudine,
abacavir, didanosine, stavudine and zalcitabine28,29. However, the three
highest frequencies of PI mutations observed in the samples were L63PI,
L10FIRV, M36I; these mutations contribute to resistance only when other
mutations are present20,24. Of all the mutations, D67N, K103 N, M184V,
in RT and L10FIRV, M46IL, L63PI, and A71TV in PI showed a significant
association with VF in this study (p = 0.03, 0.013, 0.002, 0.028, 0.033,
0.009, and 0.041, respectively), when present alone or in combination
with other mutations. This association disappeared when a logistic
regression analysis was done with all the mutation together.
In the basal sample four of 14 samples could be sequenced showing
the mutation M41L and two of them showed two or three more
mutations associated with drug resistance.
DISCUSSION
The study population was mainly comprised of men who have sex
with men and was compared with basal samples from the study groups
Table 1
Association between virological failure (VF) and risk factors
Factor Control Patients p value
group (%) group (%)
Adherence 52/53 (82.5) 11/59 (17.5) 0.000
Depression 17/28 (37) 29/33 (63) 0.015
Professional or technical 30/61 (68) 14/60 (32) 0.003
University education 26/43 (59) 18/48 (41) 0.03
Ingestion of alcohol 24/53 (41.4) 34/52 (58.6) 0.04
Initial viral load
> 104 copies/mL 58/60 (67) 29/33 (33) 0.10*
AIDS or ARC 11/62 (20) 44/64 (80) 0.000
Initial zidovudine,
lamivudine, Indinavir 45/71 (60) 30/68 (40) 0.023
Initial zidovudine,
lamivudine, nelfinavir 10/71 (28.6) 25/68 (71.4) 0.002
Resistance mutation 4/12 (7) 54/62 (93) 0.000
Change of treatment 25/71 (28.7) 62/71(71.3) 0.000
* No significative
Table 2
Distribution of different mutations to RT and PT in the 66 VF patient samples
(PS) and in 17 basal samples (BS), collected during 2003
Mutation RT-PS RT-BS PT-PS PT-BS
(%) (%) (%) (%)
M41L-L63PI 31 (47) 4 (23) 38 (57) 3 (18)
M184V-L10FIRV 28 (42) 1 (6) 21 (32) -
T215FY-M36I 25 (38) 3 (18) 18 (27) 1 (6)
K103N-A71TV 23 (35) 1 (6) 18 (27) -
D67N-M46IL 21 (32) - 16 (24) -
K219EQ-N88DS 14 (21) - 15 (23) -
L210W-L90M 13 (20) 1 (6) 13 (20) -
L74V-D30N 11 (17) 2 (12) 9 (14) -
K70R-I54LTV 11 (17) - 8 (12) -
L100I-V82AT 8 (12) - 7 (11) 1 (6)
V179DE-K20MR 7 (11) - 7 (11) -
K101EQ-L24I 7 (11) - 2 (3) -
V118I-I84V 7 (11) - 2 (3) -
V75ITV-V32I 5 (8) 1 (6) 1 (2) -
V108I-L33F 5 (8) 1 (2) -
G190AS-I47V 4 (6) - 1 (2) -
Y188L-G48V 3 (5) 1 (6) 1 (2) -
E44D 2 (3) - - -
T69D 2 (3) - - -
Q151M 2 (3) - - -
P225H 2 (3) - - -
F77I 1 (2) - - -
A98G 1 (2) - - -
Fig. 2 - Viral load in 60 basal samples of the control group (BC), 33 basal samples of the VF
patient (BP), 68 last sample in the control group (CG), and 43 last sample in the VF patient
(PG), analyzed during 2003.
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(control and VF patients); both showed high viral load and low CD4 in
basal samples, as has been observed in overall HIV positives population
in Costa Rica (HIV Control Department, Ministry of Health, Costa
Rica).
A measurement of plasma HIV-1 viral load is included in the
standard care procedure for management of all HIV-1 infected
individuals. This determination provides prognostic information for a
more efficacious therapeutic intervention. However, treatment failure
occurs and is influenced by several risk factors; the most important
one in this study was patient compliance to the ARV drugs in use.
The assays used to detect mutations (Visible Genetics) are customer
friendly, provide reliable and reproducible results; however, personnel
training is an extremely important requirement. The software was very
reliable too, although the editing process as well is also very
important10,12,14..
In this study no relationship was found between the outcome of
treatment and the basal CD4 levels or basal viral loads in opposition to
other studies2,12,16,22. Earlier data collected in 1998 at the beginning of
HAART in Costa Rica (unpublished), showed no relationship between
basal viral load and outcome of ART (r = 0.272), but an association
was observed with the basal CD4 levels (r = 0.045). In that study most
of the VF were probably related to adherence, and other factors like
clinical presentation, ART access and for all these factors, the existence
of multiple resistant mutants that could not be taken into consideration
due to absence of genotyping analysis before treatment changes.
The fact that more patients were adherent with zidovudine,
lamivudine and indinavir than zidovudine, lamivudine and nelfinavir
was controversial since indinavir treatment is relatively more difficult
to comply, and it causes more severe secondary effects. However,
indinavir is a more potent drug than nelfinavir and that may be the
reason for patients under this drug to have a better outcome18,31,32.
The most frequent mutations found in the RT in this study (Table
2), cause total or partial resistance to zidovudine, stavudine, lamivudine,
didanosine, zalcitabine, and abacavir28,29. It is noteworthy that the three
first drugs mentioned above were included in the initial triple treatment
scheme of these patients. The NNRT resistant prevalence was 43%,
with mutants L103 N present in 31% of the samples showing drug
resistance to all three NNRT drugs used7,24.
The mutations, D67N, K103 N, M184V, in RT and L10FIRV,
M46IL, L63PI, and A71TV in PI showed a significant association with
VF in this study, however, in order to disclose the importance of these
mutations a logistic regression analysis was done and the loosing of
significance found, showed that all mutations are interrelated, therefore
it is not possible to establish the difference in weight of each one in
the VF.
The study showed that very few resistant mutants to HIV antiviral
drugs were detected on basal samples in this population (Table 2) and
the ones present did not condition the outcome of treatment.
In summary, there seems to be an urgent need to detect resistant
mutants, whenever there is a treatment failure, to guide the physician
in the choice of a new ART scheme3,4,6,7,9,13,23. Also, it would be important
to reevaluate the “basal status” of patients going into HAART because
with its use during many years, the HIV positive population can
accumulate resistant mutants, which could interfere with the outcome
of initial treatment3,4,20,21,27. However, mutations associated to resistance
were found only in two of 11 basal samples taken during 2003 and
sequenced during this year (data not shown).
By far, as noted the most important factor related to treatment
response was adherence, in agreement to other studies2,5,15,26,30. Therefore
physicians should consider adopt a more aggressive approach to
improve the level of ARV drug adherence as a way to obtain a better
treatment outcome.
RESUMEN
Estudio de mutantes resistentes a los antiretrovirales en
pacientes con VIH con falla terapeutica y efecto de los factores
de riesgo en el tratamiento
En Costa Rica no se tiene información a cerca de genotipos de
resistencia para los tratamientos anti-retrovirales disponibles y la
influencia de diferentes factores de riego en la falla virológica (FV) de
pacientes VIH positivos previo o durante su tratamiento.
Ochenta y nueve muestras, 72 FV y 17 basales, fueron analizadas
con Trugene o LIPA para la detección de mutantes de resistencia en la
transcriptasa reversa (TR) y en la proteasa (PT) del VIH. Se
seleccionaron sesenta y ocho controles y se recolectó información
relevante en un cuestionario.
La mala adherencia, la presencia de mutaciones y el número de
cambios de tratamiento fueron los únicos factores con significancia
encontrados. (p = 0.03, 0.04 and 0.04 respectively). De 66 muestras
secuenciadas, 78%, 50% y 50% mostraron resistencia a los inhibidores
análogos y no análogos de nucleótidos para la TR y la PT
respectivamente. La mutaciones más frecuentes fueron M41L, M184V,
y T215FY en la TR y L62PI, L10FIRV y M36I en la PT.
La adherencia fue el factor más importante relacionado con la
respuesta al tratamiento. Las mutaciones encontradas en la TR estaban
relacionadas al tratamiento mientras que las de la PT fueron mutaciones
secundarias que propician la aparición de las mutaciones asociadas a
resistencia en esa región. Este estudio revela la necesidad de detectar
mutantes de resistencia en pacientes con FV y de estudiar las muestras
basales. Además la importancia de reforzar la adherencia en los
pacientes para una mejor respuesta al tratamiento.
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